Kyntra Bio holders back director, pay and auditor

Kyntra Bio, Inc. reported results from its 2026 annual stockholder meeting held on June 12, 2026.

(Moderate)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Kyntra Bio, Inc. reported results from its 2026 annual stockholder meeting held on June 12, 2026. Stockholders elected Class III director Michael Kauffman, M.D., Ph.D., to serve until the 2029 annual meeting, with 1,239,169 votes for, no votes against, 51,081 withheld, and 1,444,428 broker non-votes.

Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers, with 1,242,005 votes for, 23,606 against, 24,639 abstentions, and 1,444,428 broker non-votes. In addition, they ratified the Audit Committee’s selection of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026, with 2,712,825 votes for, 14,392 against, and 7,461 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Director election votes for: 1,239,169 shares Director election withheld: 51,081 shares Broker non-votes (Proposals 1 and 2): 1,444,428 shares +4 more

7 metrics

Director election votes for 1,239,169 shares Votes for Class III director Michael Kauffman, M.D., Ph.D.

Director election withheld 51,081 shares Withheld votes for Class III director election

Broker non-votes (Proposals 1 and 2) 1,444,428 shares Broker non-votes on director election and say-on-pay

Say-on-pay votes for 1,242,005 shares Advisory approval of named executive officer compensation

Say-on-pay votes against 23,606 shares Votes against executive compensation advisory proposal

Auditor ratification votes for 2,712,825 shares Ratification of PricewaterhouseCoopers LLP for 2026

Auditor ratification votes against 14,392 shares Votes against ratifying PricewaterhouseCoopers LLP

Key Terms

broker non-votes, named executive officers, independent registered public accounting firm, Emerging growth company

4 terms

broker non-votes financial

"1,239,169 shares of Common Stock voted for, 0 against, 51,081 withheld, and 1,444,428 broker non-votes."

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

named executive officers financial

"The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 definitive proxy statement"

Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.

independent registered public accounting firm financial

"the selection of PricewaterhouseCoopers LLP ... as the independent registered public accounting firm of the Company for the year ending December 31, 2026"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

Emerging growth company regulatory

"Emerging growth company Item 5.07 Submission of Matters to a Vote of Security Holders."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kyntra Bio (KYNB) shareholders decide at the 2026 annual meeting?

Shareholders elected one Class III director, approved executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor for 2026. These votes confirm the existing board structure, pay programs, and audit firm relationship for the coming year.

How did Kyntra Bio (KYNB) shareholders vote on director Michael Kauffman?

Shareholders elected Michael Kauffman, M.D., Ph.D., as a Class III director through the 2029 annual meeting, with 1,239,169 votes for, none against, 51,081 withheld, and 1,444,428 broker non-votes. The strong support indicates broad backing for his continued service on the board.

Was Kyntra Bio (KYNB) executive compensation approved by shareholders?

Yes, shareholders approved Kyntra Bio’s named executive officer compensation on an advisory basis, with 1,242,005 votes for, 23,606 against, 24,639 abstentions, and 1,444,428 broker non-votes. This non-binding vote indicates shareholder acceptance of the company’s 2026 pay practices as disclosed.

Which audit firm will serve Kyntra Bio (KYNB) for 2026 and how was it ratified?

PricewaterhouseCoopers LLP was ratified as Kyntra Bio’s independent registered public accounting firm for the year ending December 31, 2026. Shareholders cast 2,712,825 votes for, 14,392 against, and 7,461 abstentions, signaling broad support for continuing the existing audit relationship.

What were the broker non-vote totals at Kyntra Bio’s 2026 annual meeting?

Broker non-votes totaled 1,444,428 shares on both the director election and the advisory vote on executive compensation. Broker non-votes typically arise when beneficial owners do not provide voting instructions on non-routine proposals presented at the meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/15/2026 - 07:23 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 12, 2026

    

KYNTRA BIO, INC.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-36740	77-0357827
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

350 Bay Street Suite 100 #6009
San Francisco, California		94133
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 415 978-1200 

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.01 par value	KYNB	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

At the 2026 annual meeting of stockholders of Kyntra Bio, Inc. (“Kyntra Bio” or the “Company”) held on June 12, 2026, the stockholders voted on the three proposals listed below. The proposals are described in detail in the Company’s definitive proxy statement for the 2026 annual meeting of stockholders, filed with the Securities and Exchange Commission on April 27, 2026. The results of the matters voted upon at the meeting were:


(1)		The Class III director nominee, Michael Kauffman, M.D., Ph.D., was elected to hold office until the Company’s 2029 annual meeting of stockholders. The director received 96.04% of the shares voting: 1,239,169 shares of Common Stock voted for, 0 against, 51,081 withheld, and 1,444,428 broker non-votes. The term of office of Class I directors Thane Wettig, James A. Schoeneck, and Maykin Ho, Ph.D. continues until the Company’s 2027 annual meeting of stockholders. The term of office of Class II director Jeffrey L. Edwards continues until the Company’s 2028 annual meeting of stockholders.
(2)		The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 definitive proxy statement filed on April 27, 2026: 1,242,005 shares of Common Stock voted for, 23,606 against, 24,639 abstaining, and 1,444,428 broker non-votes.
(3)		The stockholders ratified the selection of PricewaterhouseCoopers LLP, by the Audit Committee of the Kyntra Bio board of directors, as the independent registered public accounting firm of the Company for the year ending December 31, 2026: 2,712,825 shares of Common Stock voted for, 14,392 against, and 7,461 abstaining.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			KYNTRA BIO, INC.

Date:	June 15, 2026	By:	/s/ John Alden
			John Alden General Counsel

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document